<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149418</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1262</org_study_id>
    <secondary_id>A074000</secondary_id>
    <secondary_id>AG&amp;LSC/FOOD SCIENCE/FOOD SCIEN</secondary_id>
    <nct_id>NCT04149418</nct_id>
  </id_info>
  <brief_title>Yogurt for Prevention of Chronic Inflammation</brief_title>
  <official_title>Anti-inflammatory Activity of Yogurt Mediated by the Intestine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Dairy Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Amherst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to conduct a randomized cross-over dietary intervention in
      obese adult women to compare how yogurt and a control food affect biomarkers of inflammation
      and intestinal health.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Th17 proportion</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportions of circulating Th17 cells (change in control vs. change in yogurt)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Treg proportion</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Treg cells (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treg subpopulation</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Treg subpopulation (FoxP3+ IL-10+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 subpopulation (IL-17A+ TNFα+)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Th17 subpopulation (IL-17A+ TNFα+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 subpopulation (IL-17A+ IFNδ+)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Th17 subpopulation (IL-17A+ IFNδ+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 subpopulation (IL-17A+ IL-22+)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Th17 subpopulation (IL-17A+ IL-22+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 subpopulation (IL-17A+ FoxP3+)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Th17 subpopulation (IL-17A+ FoxP3+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 subpopulation (IL-17A+ IL-10+)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in proportion of circulating Th17 subpopulation (IL-17A+ IL-10+) (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma tumor necrosis factor alpha (TNF-alpha)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma TNF-alpha (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interferon gamma (IFN-gamma)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IFN-gamma (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interleukin-6 (IL-6)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IL-6 (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interleukin-17A (IL-17A)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IL-17A (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interleukin-4</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IL-4 (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interleukin-22 (IL-22)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IL-22 (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma interleukin-10 (IL-10)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma IL-10 (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma transforming growth factor beta (TGF-beta)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma TGF-beta (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinoic acid receptor-related orphan nuclear receptor gamma T (RORgammaT) expression</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting plasma RORgammaT expression (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forkhead box P3 (FoxP3) expression</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fasting FoxP3 expression (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal calprotectin</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal calprotectin (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal tumor necrosis factor alpha (TNF-alpha)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal TNF-alpha (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal interleukin 1 alpha (IL-1alpha)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal IL-1alpha (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal interleukin 1beta (IL-1beta)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal IL-1beta (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal interleukin-6 (IL-6)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal IL-6 (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal interleukin-17A (IL-17A)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal IL-17A (change in control vs. change in yogurt)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in resting systolic blood pressure (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in resting diastolic blood pressure (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Body mass index (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in body weight (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in waist circumference (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance: Number of lids and Unused Containers</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Number of lids and unused containers of intervention foods (control vs. yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary records</measure>
    <time_frame>2 Weeks Prior to Intervention, Weeks 0-4, Weeks 4-8, Weeks 8-12</time_frame>
    <description>Comparison of dietary records (control vs. yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gut microbiota diversity</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in gut microbiota beta diversity (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal water ex vivo barrier disrupting activity</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in barrier disrupting activity of fecal water applied to cultured Caco-2 cells (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal total organic carbon</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in total organic carbon (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal butyrate</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal butyrate (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal propionate</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal propionate (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal acetate</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal acetate (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal bile acid (deoxycholic acid)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal deoxycholic acid (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal bile acid (lithocholic acid)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal lithocholic acid (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal bile acid (hyodeoxycholic acid)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal hyodeoxycholic acid (change in control vs. change in yogurt)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fecal bile acid (3β,12α-Dihydroxy-5β-cholan-24-oic acid)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
    <description>Change in fecal 3β,12α-Dihydroxy-5β-cholan-24-oic acid (change in control vs. change in yogurt)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Obesity</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Yogurt-Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-Yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Yogurt</intervention_name>
    <description>Low-fat flavored yogurt</description>
    <arm_group_label>Control-Yogurt</arm_group_label>
    <arm_group_label>Yogurt-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control food</intervention_name>
    <description>Low-fat flavored soy pudding</description>
    <arm_group_label>Control-Yogurt</arm_group_label>
    <arm_group_label>Yogurt-Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy premenopausal women age 21-55

          -  BMI 30 to 40 kg/m2

          -  not taking medication to control hypertension (e.g. anti-hypertensives or diuretics)

          -  resting blood pressure &lt;140/90 mmHg

          -  stable body weight for past two months

          -  willing to maintain a normal exercise level (in general)

          -  willing to avoid exercise and smoking (or other forms of nicotine intake) for 24 h
             prior to blood collection

          -  willing to avoid caffeine for 12 h before study visits

          -  willing to fast 12 h prior to study visits

          -  willing to avoid dietary supplements, yogurt and probiotic-containing foods (as
             necessary) and consume 12 oz. of yogurt and the control food per day (as necessary)
             for the duration of the study

        Exclusion Criteria:

          -  self-reported previous diagnoses of an inflammatory disease (e.g. inflammatory bowel
             disease, asthma, arthritis), CVD, diabetes, current cancer treatment (i.e.,
             chemotherapy, radiation therapy)

          -  have used oral antibiotics in the prior 21 days before sample collection

          -  actively trying to lose weight

          -  regularly taking anti-inflammatory drugs

          -  vegetarian or allergic to soy or dairy

          -  are pregnant, lactating, or trying to become pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley W Bolling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bradley W Bolling, PhD</last_name>
    <phone>608-890-0212</phone>
    <email>bwbolling@wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Food Science, Babcock Hall</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>yogurt</keyword>
  <keyword>obesity</keyword>
  <keyword>intestine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

